|
FDA Advisory Panel Narrowly Favors Approval of Genzyme HoFH Drug
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 9–6 Thursday to recommend approval of Genzyme and Isis Pharmaceuticals’ homozygous familial hypercholesterolemia (HoFH) drug Kynamro.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives